ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

Merck is going all-in on domestic drug manufacturing with a $1 billion Delaware facility aimed at dodging Trump-era tariff ...

DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.